Clinical trial NCT02631941: Clinical Study to Evaluate Z7200 Pharmacokinetics Profile
Official title: An Open-Label, Randomized, Five-Period Cross-over, Single-dose Study to Compare Pharmacokinetics Profiles of Z7200 Medium Strength and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Asthma
Lead sponsor: Zambon SpA
Sponsor class: INDUSTRY
First posted: 2015-12-16
Enrollment: 91
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Brief Summary:

The primary objective was:

* to assess the bioequivalence of a single dose (two inhalations) of the test product compared to the reference product, with and without charcoal blockade.

The secondary objectives were:

* to assess the pharmacokinetic profile of budesonide and formoterol in plasma after a single dose (two inhalations) of the test product and the reference product, with and without charcoal blockade.
* to assess the safety and tolerability of the test product and the reference product, with and without charcoal blockade.

Detailed description: This was a single center, open label, randomized, five-period crossover, single-dose study in healthy volunteers aged 18 to 45 years. A total of 90 volunteers were planned to be enrolled, with 9 subjects in each of the 10 treatment sequences.

The study consisted of 5 treatment periods, each lasting approximately 48h, separated by a washout period of a minimum of 5 days. RS01 and/or Symbicort Turbohaler device use training was provided on Day -1 and Day 1 of each treatment period. Subjects were screened for eligibility to participate in the study -28 to -2 days prior to the first treatment period, and were randomized to one of 10 treatment sequences containing the following 5 treatment arms on Day 1 of the first treatment period:

Treatment A: Z7200 without oral activated charcoal\* Treatment B1: Symbicort 1 without oral activated charcoal\* Treatment B2: Symbicort 2 without oral activated charcoal\* Treatment C: Z7200 with oral activated charcoal\*\* Treatment D: Symbicort with oral activated charcoal\*\*

Subjects were admitted to the clinical unit at 8.00 on the morning of Day -1, and were dosed on the morning of Day 1 following an overnight fast (minimum of 8h). On Day 2, following collection of the 24-h PK blood sample, subjects were discharged.

\* Subjects who received treatments A, B1 and B2 rinsed their mouth vigorously with 50 mL water for 3 to 5 sec immediately after the second inhalation.

\*\* A charcoal blockade was used to prevent absorption from oropharyngeal and GI tract, in order to assess the pulmonary deposition of budesonide and formoterol, with periods performed without a charcoal blockade allowing the assessment of the total systemic exposure to the drug.

Eligibility criteria: Main Inclusion Criteria:

* Male or female 18 to 45 years of age.
* If female, is currently not pregnant/breast feeding/ or attempting to become pregnant has a negative serum pregnancy test, or is of non-childbearing potential or is of child-bearing potential, willing to commit to using a consistent and acceptable method of birth control or is of child-bearing potential and not sexually active
* Body mass index (BMI) of 18.0 to 32.0 kg/m² inclusive and a body weight ≥50 kg.
* 10 years or more past history of cigarette, \<=5 pack year

Main Exclusion Criteria:

* Forced Expiratory Volume in 1 sec (FEV1) value less than 80% of the predicted value and FEV1/FVC (Forced Vital Capacity) ratio \<0.7.
* History or current evidence of a clinically significant disease or disorder capable of altering the absorption, metabolism, distribution or elimination of drugs.
* History or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, haematological, neuropsychological, endocrine, gastrointestinal or pulmonary.
* Presence of glaucoma, cataracts, ocular herpes simplex, malignancy, regardless of the clinical significance or current stability of the disease.
* positive tests for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C.
* Bacterial or viral infection of the upper respiratory tract (including the common cold and flu), sinus, or middle ear within 2 weeks of dosing.
* Lower respiratory tract infection/pneumonia within the past 3 months.
* Presence of any disease or condition or regular concomitant treatment (including vitamins and herbal products) known to interfere with the absorption, distribution, metabolism or excretion of drugs.
* Screening haemoglobin value of less than 1g/dL above the Lower Limit of Normality
* History of recurrent vasovagal collapses.
* History of anaphylactic/anaphylactoid reactions.
* History of seizures including febrile seizures excluding childhood febrile convulsions.
* Unable to demonstrate proper inhalation techniques involved in using the delivery devices at screening.
* Exposure to any investigational drug within 90 days of the Screening Visit.
* Known or suspected hypersensitivity or idiosyncratic reaction to any steroid, any β2 agonist; allergy to milk protein.
* Use of an inhaled corticosteroid within 30 days or systemic corticosteroid within 60 days of the Screening Visit.
* Use of medications or herbal medicines that are strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 30 days prior to Screening Visit
* Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study.
* Use of caffeine containing beverages more than 5 cups/day.
* Recent or current (suspected) drug abuse or positive result in the drugs abuse test.
* Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 14 units per week for females)
* Predictable poor compliance, intolerance to charcoal solution, or inability to communicate well with the study centre personnel or inability to participate in all treatment periods.

Primary outcomes:
measure: AUC0-last of Budesonide With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: AUC0-last of Formoterol With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: Cmax of Budesonide With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: Cmax of Formoterol With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Secondary outcomes:
measure: AUC0-30 of Budesonide With and Without Charcoal Blockade.
timeFrame: 0-30 min (0, 2, 5, 10, 15, 20, and 30 min)
measure: AUC0-30 of Formoterol With and Without Charcoal Blockade.
timeFrame: 0-30 min (0, 2, 5, 10, 15, 20, and 30 min)
measure: AUC0-∞ of Budesonide With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: AUC0-∞ of Formoterol With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: Tmax for Budesonide With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: Tmax for Formoterol With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: t1/2 for Budesonide With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: t1/2 for Formoterol With and Without Charcoal Blockade
timeFrame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
measure: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: At 75 min (1.25 hours) post-dose
measure: Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)
timeFrame: At 75 min (1.25 hours) post-dose
measure: Change From Baseline in Peak Expiratory Flow Rate (PEFR)
timeFrame: At 75 min (1.25 hours) post-dose
Other outcomes:
Locations:
city: Ruddington
country: United Kingdom
facility: Quotient Clinical Ltd
Study officials:
affiliation: Quotient Clinical Limited
name: Sharan Sidhu, MBChB
role: PRINCIPAL_INVESTIGATOR
References: